← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Metaclipse Therapeutics Corporation
Atlanta, GA
$8,832,234
Total funding
6
Grants
Funding over time
peak $2.2M · FY2013–25$2.5M$1.9M$1.3M$625K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,832,234 · 6
By mechanism
N44$4,148,210 · 1
R44$3,954,038 · 2
N43$585,227 · 2
R43$144,759 · 1
Investigators at Metaclipse Therapeutics Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development of a SARS-CoV-2 vaccine for the elderly by engineering virus-like particles with SARS-CoV-2 antigen and membrane-anchored cytokines$2,199,976
N44 · FY2020 · AI
Development of Membrane Anchored Cytokines as Novel Vaccine Adjuvants for the Elderly$1,948,234
N44 · FY2019 · AI
Membrane-based vaccine with checkpoint blockade for triple negative breast cancer$1,079,344
R44 · FY2018 · CA
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer$1,061,403
R44 · FY2021 · CA
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer$938,597
R44 · FY2022 · CA
Membrane-based vaccine with checkpoint blockade for triple negative breast cancer$700,539
R44 · FY2017 · CA
SBIR CONCEPT AWARD FOR DEVELOPMENT OF THERAPEUTIC OR PREVENTATIVE TECHNOLOGIES FOR TREATMENT OR PREVENTION OF PEDIATRIC CANCERS AND/OR RARE CANCERS$354,957
N43 · FY2025 · CA
Development of membrane anchored cytokines as novel vaccine adjuvants for the elderly$230,270
N43 · FY2017 · AI
A membrane-based immunotherapy for triple negative breast cancer$144,759
R43 · FY2013 · CA
IND enabling studies for a personalized immunotherapy for triple negative breast cancer$80,133
R44 · FY2019 · CA
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer$59,382
R44 · FY2022 · CA
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer$34,640
R44 · FY2022 · CA